Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Mattison

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Radiology|October 4, 2022
Multicenter Reproducibility of Liver Iron Quantification with 1.5-T and 3.0-T MRIDiego Hernando, Ruiyang Zhao, Qing Yuan, et al.
Leukemia & Lymphoma|June 5, 2024
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trialVikas Gupta, Abdulraheem Yacoub, Ruben A Mesa, et al.
Journal of Magnetic Resonance Imaging : JMRI|April 25, 2024
Practical Application of Multivendor MRI-Based R2* Mapping for Liver Iron Quantification at 1.5 T and 3.0 TGregory Simchick, Ruiyang Zhao, Qing Yuan, et al.
Blood Advances|September 7, 2021
Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALLMatthew J Wieduwilt, Jun Yin, Meir Wetzler, et al.
Magnetic Resonance in Medicine|September 6, 2024
Multicenter, multivendor validation of liver quantitative susceptibility mapping in patients with iron overload at 1.5 T and 3 TCollin J Buelo, Julia Velikina, Lu Mao, et al.
Cancer|June 17, 2015
A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network studyTimothy S Fenske, Namrata M Shah, Kyung Mann Kim, et al.
Leukemia & Lymphoma|September 21, 2020
Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemiaMuhammad Umair Mushtaq, Alexandra M Harrington, Sibgha Gull Chaudhary, et al.
Blood Advances|February 18, 2026
CRLF2-rearrangement and Extramedullary Disease in B-cell Acute Lymphoblastic Leukemia: A Possible Link?Flavia Gava, Bonnie Yates, Zhouxin Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant ErythropoietinAlan F List, Zhuoxin Sun, Amit Verma, et al.
Blood Advances|May 27, 2020
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomabTalha Badar, Aniko Szabo, Anjali Advani, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Radiology|October 4, 2022
Multicenter Reproducibility of Liver Iron Quantification with 1.5-T and 3.0-T MRIDiego Hernando, Ruiyang Zhao, Qing Yuan, et al.
Leukemia & Lymphoma|June 5, 2024
Safety and efficacy of fedratinib in patients with myelofibrosis previously treated with ruxolitinib: primary analysis of FREEDOM trialVikas Gupta, Abdulraheem Yacoub, Ruben A Mesa, et al.
Journal of Magnetic Resonance Imaging : JMRI|April 25, 2024
Practical Application of Multivendor MRI-Based R2* Mapping for Liver Iron Quantification at 1.5 T and 3.0 TGregory Simchick, Ruiyang Zhao, Qing Yuan, et al.
Blood Advances|September 7, 2021
Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALLMatthew J Wieduwilt, Jun Yin, Meir Wetzler, et al.
Magnetic Resonance in Medicine|September 6, 2024
Multicenter, multivendor validation of liver quantitative susceptibility mapping in patients with iron overload at 1.5 T and 3 TCollin J Buelo, Julia Velikina, Lu Mao, et al.
Cancer|June 17, 2015
A phase 2 study of weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network studyTimothy S Fenske, Namrata M Shah, Kyung Mann Kim, et al.
Leukemia & Lymphoma|September 21, 2020
Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemiaMuhammad Umair Mushtaq, Alexandra M Harrington, Sibgha Gull Chaudhary, et al.
Blood Advances|February 18, 2026
CRLF2-rearrangement and Extramedullary Disease in B-cell Acute Lymphoblastic Leukemia: A Possible Link?Flavia Gava, Bonnie Yates, Zhouxin Sun, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 13, 2021
Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant ErythropoietinAlan F List, Zhuoxin Sun, Amit Verma, et al.
Blood Advances|May 27, 2020
Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with blinatumomabTalha Badar, Aniko Szabo, Anjali Advani, et al.
Pageof 8